dendrogenin b

Dendrogenin B (DDB) is a steroidal alkaloid small molecule and a mammalian cholesterol metabolite developed by the French biotechnology company Affichem. As a member of the novel dendrogenin class, DDB functions as a potent inducer of cell differentiation in neuronal and immuno-competent cells. Preclinical research has demonstrated its potential in treating various forms of hearing loss, specifically targeting neuropathy and synaptopathy-related deafness, and it is being explored for its ability to enhance the efficacy of cochlear implants. Beyond otology, Dendrogenin B exhibits neurostimulating and potential anticancer properties, representing a new therapeutic approach using sterol-derived metabolites to modulate cell fate and survival.

Other names

dendrogenine b